SG Americas Securities LLC cut its stake in shares of Baxter International Inc. (NYSE:BAX – Get Rating) by 49.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 28,815 shares of the medical instruments supplier’s stock after selling 28,244 shares during the period. SG Americas Securities LLC’s holdings in Baxter International were worth $1,552,000 as of its most recent filing with the SEC.
Several other large investors have also recently bought and sold shares of the stock. Community Bank N.A. boosted its position in Baxter International by 8.1% during the third quarter. Community Bank N.A. now owns 18,087 shares of the medical instruments supplier’s stock valued at $974,000 after purchasing an additional 1,352 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its stake in Baxter International by 538.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 12,881 shares of the medical instruments supplier’s stock valued at $694,000 after buying an additional 10,862 shares during the period. John G Ullman & Associates Inc. raised its stake in Baxter International by 2.5% in the third quarter. John G Ullman & Associates Inc. now owns 66,734 shares of the medical instruments supplier’s stock valued at $3,594,000 after buying an additional 1,657 shares during the period. Empirical Asset Management LLC bought a new stake in Baxter International in the third quarter valued at approximately $474,000. Finally, Plimoth Trust Co. LLC raised its stake in Baxter International by 10.9% in the third quarter. Plimoth Trust Co. LLC now owns 4,523 shares of the medical instruments supplier’s stock valued at $244,000 after buying an additional 445 shares during the period. 84.84% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several analysts have issued reports on BAX shares. Deutsche Bank Aktiengesellschaft lowered Baxter International from a “buy” rating to a “hold” rating and dropped their price objective for the company from $69.00 to $51.00 in a research note on Thursday, December 15th. KeyCorp lowered their target price on Baxter International from $77.00 to $73.00 and set an “overweight” rating on the stock in a research note on Friday, October 28th. Wells Fargo & Company lowered their target price on Baxter International from $57.00 to $52.00 and set an “equal weight” rating on the stock in a research note on Monday, January 9th. The Goldman Sachs Group lowered their target price on Baxter International from $60.00 to $53.00 and set a “sell” rating on the stock in a research note on Thursday, November 3rd. Finally, TheStreet lowered Baxter International from a “c” rating to a “d+” rating in a research note on Thursday, October 27th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $62.93.
Baxter International Price Performance
Baxter International (NYSE:BAX – Get Rating) last issued its earnings results on Thursday, October 27th. The medical instruments supplier reported $0.82 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.82. The firm had revenue of $3.77 billion for the quarter, compared to the consensus estimate of $3.77 billion. Baxter International had a positive return on equity of 22.65% and a negative net margin of 16.12%. As a group, research analysts expect that Baxter International Inc. will post 3.56 EPS for the current fiscal year.
Baxter International Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, January 3rd. Shareholders of record on Friday, December 2nd were issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date of this dividend was Thursday, December 1st. Baxter International’s dividend payout ratio is presently -24.58%.
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
- Get a free copy of the StockNews.com research report on Baxter International (BAX)
- General Electric Stock, The Sum of All Parts Strategy is Paying Off
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.